RxDoctor Payments Data

Linda Prokai

Physician Assistant · Carmel, INNPI 1154540847

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,152 of the $10,189 with a category attached, or 89.8%. 40 manufacturers reported payments, led by AbbVie at 27.2% of the total. Reporting peaked in 2021 at $3,013 and has fallen 62.4% since, to $1,132 in 2025. Among physician assistant clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$10,189in general payments, 2019–2025

Across 509 payments — averaging $20.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Neurocrine Biosciences, Inc.$619
  • Lundbeck LLC$388
  • Pfizer$290
  • plus $4K from 34 others

What the payments were for

  • Consulting fees$8008%
  • Travel & lodging$671%
  • Food & beverage$9,15290%
  • Education$1702%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,189 in reported general payments places this provider in the 95th percentile of 1,955 physician assistant providers in Indiana.

See all physician assistant providers in Indiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$96,851
Invega SustennaPaliperidone Palmitate14$36,194
Abilify MaintenaAripiprazole13$35,968
Buprenorphine92$25,266
BelbucaBuprenorphine Hcl26$24,238
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl266$22,826
Aimovig AutoinjectorErenumab-Aooe26$19,474
ButransBuprenorphine25$10,236
Emgality PenGalcanezumab-Gnlm14$9,397
BelsomraSuvorexant15$8,265
Buprenorphine Hcl178$5,973
Armodafinil35$4,489
Lurasidone Hcl23$4,103
Aripiprazole30$3,102
Naltrexone Hcl49$2,469

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$619$96,85112 claims
Johnson & JohnsonInvega Sustenna$45$36,19414 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$115$35,96813 claims
Collegium Pharmaceutical, Inc.Belbuca$232$24,23826 claims
MerckBelsomra$273$8,26515 claims
Almatica Pharma LLCSertraline Hcl$103$74097 claims
Upsher-smith Laboratories LLCTopiramate$20$63468 claims
Lilly USA, LLCOlanzapine$166$57815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,955 physician assistant providers in Indiana.

Other physician assistant in Carmel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →